ROBOSENSE
RoboSense, a leading automotive LiDAR manufacturer, announced today that it has obtained the IATF 16949 certificate in the automotive field, which now fully qualifies it to supply to automotive customers. RoboSense’s LiDAR production line obtained the IATF 16949 Letter of Conformity in December, which has accelerated partnerships of automotive-grade LiDAR serial productions with major OEMs and Tier 1s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200207005157/en/
Developed by the IATF (International Automotive Task Force) and submitted to the International Organization for Standardization (ISO) for approval and publication, IATF 16949 is the most widely used global quality management standard for the automotive industry. In addition, the high quality management that IATF 16949 offers utilizes 5 tools (APQP/FMEA/MSA/SPC/PPAP) as part of their application assessment.
Dr. LeiLei Shinohara, the Co-partner and Vice President of RoboSense, said, "IATF16949 requires extremely high production consistency, and emphasizes various product reliability metrics. It recognizes the RoboSense design, research and development, and production processes. It also indicates that RoboSense has achieved a new milestone of complete readiness for serial mass production of automotive LiDARs, including the latest solid-state smart LiDAR "RS-LiDAR-M1".”
RoboSense's "125-layer equivalent" solid-state LiDAR "RS-LiDAR-M1" was officially released in January 2020 as the world’s first MEMS LiDAR to obtain IATF6949 for its production line. Its production was carried out under the IATF16949 quality management system.
The product development of "RS-LiDAR-M1" followed the APQP and A-SPICE as the basis for the project management and product development process. During production, RoboSense fully implemented the IATF16949 quality management system and ISO26262 functional safety standards. By combining ISO16750 test requirement and other automotive-grade reliability specifications with these systems, the accuracy of the RS-LiDAR-M1 product can be verified.
MEMS mirror is the core component in RS-LiDAR-M1. According to the AEC-Q100 standard, combining the characteristics of MEMS micro-mirror, a total of ten verification test groups were designed, covering factors such as: temperature, humidity, packaging process, electromagnetic compatibility, mechanical vibration and shock, and aging. The cumulative test time for all test samples has now exceeded 100,000 hours. Furthermore, the longest-running prototype has been tested for more than 300 days, while the total road test mileage has exceeded 150,000 kilometers with no degradation found in various testing scenarios.
In Vienna, Austria, the RS-LiDAR-M1 was tested for rain and fog under different light and wind speed conditions. The test results prove that the RS-LiDAR-M1 has met the required standards and the final mass-produced RS-LiDAR-M1 will adapt to all climate and working conditions.
RoboSense continues to optimize the LiDAR performance in order to lead the way towards a driverless future. On September 25, 2019, RoboSense partnered with First Automobile Works (FAW), the world's leading automotive OEM, to include RS-LiDAR-M1 as a core component in FAW's proprietary next-generation autonomous driving system development. On January 8, 2020, during CES2020, RoboSense cooperated with Freetech, the leading ADAS solution provider, on the serial production of the smart multi-sensor fusion solution.
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems. By incorporating LiDAR sensors, AI algorithms and IC chipsets, conventional 3D LiDAR sensors are transformed to full data analysis and comprehension systems. The company's mission is to provide outstanding hardware and artificial intelligence capabilities to deliver smart solutions that enable robots (including vehicles) to have perception capability more superior to humans.
About IATF
IATF members include BMW Group, Daimler AG, FCA, Ford Motor Company, General Motors Company, Jaguar Land Rover (JLR) Limited, PSA Group, Renault, Volkswagen AG and the vehicle manufacturers respective trade associations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200207005157/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom